Kerry Holford
Stock Analyst at Berenberg Bank
(4.03)
# 1,690
Out of 4,476 analysts
236
Total ratings
60.6%
Success rate
9.7%
Average return
Main Sectors:
Stocks Rated by Kerry Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0NZT UCB SA | Maintained: Buy | €130.00 → €305.00 | $257.85 | +18.29% | 3 | Jul 2, 2026 | |
| LLY Eli Lilly and Company | Maintained: Hold | $1,050 → $1,135 | $1,213.91 | -6.50% | 30 | Jun 22, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Buy | kr 300.00 → kr 325.00 | $326.48 | -0.45% | 41 | Jun 17, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $126 → $46 | $46.95 | -2.66% | 4 | Jun 16, 2026 | |
| PFE Pfizer | Maintained: Hold | $25 | $24.32 | +2.80% | 30 | May 8, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 2,000p | $2,015.00 | -0.74% | 49 | May 5, 2026 | |
| NVO Novo Nordisk | Maintained: Buy | $57 → $47 | $50.43 | -6.80% | 7 | Mar 11, 2026 | |
| NVS Novartis AG | Rated: Hold | $116 → $141 | $159.90 | -11.82% | 8 | Mar 6, 2026 | |
| GSK GSK plc | Maintained: Hold | $41 → $43 | $53.66 | -19.87% | 14 | Nov 25, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 89.00 → CHF 92.00 | $127.92 | -28.08% | 40 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €105.00 → €120.00 | $75.81 | n/a | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €1.60 | $1.75 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $60 | $83.71 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 100p | $47.10 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €150.00 | $145.65 | n/a | 1 | Apr 16, 2021 |
UCB SA
Jul 2, 2026
Maintained: Buy
Price Target: €130.00 → €305.00
Current: $257.85
Upside: +18.29%
Eli Lilly and Company
Jun 22, 2026
Maintained: Hold
Price Target: $1,050 → $1,135
Current: $1,213.91
Upside: -6.50%
Novo Nordisk A/S
Jun 17, 2026
Maintained: Buy
Price Target: kr 300.00 → kr 325.00
Current: $326.48
Upside: -0.45%
Zealand Pharma A/S
Jun 16, 2026
Downgraded: Hold
Price Target: $126 → $46
Current: $46.95
Upside: -2.66%
Pfizer
May 8, 2026
Maintained: Hold
Price Target: $25
Current: $24.32
Upside: +2.80%
GSK plc
May 5, 2026
Maintained: Hold
Price Target: 2,000p
Current: $2,015.00
Upside: -0.74%
Novo Nordisk
Mar 11, 2026
Maintained: Buy
Price Target: $57 → $47
Current: $50.43
Upside: -6.80%
Novartis AG
Mar 6, 2026
Rated: Hold
Price Target: $116 → $141
Current: $159.90
Upside: -11.82%
GSK plc
Nov 25, 2025
Maintained: Hold
Price Target: $41 → $43
Current: $53.66
Upside: -19.87%
Novartis AG
Nov 18, 2025
Maintained: Hold
Price Target: CHF 89.00 → CHF 92.00
Current: $127.92
Upside: -28.08%
May 16, 2025
Maintained: Buy
Price Target: €105.00 → €120.00
Current: $75.81
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: €1.60
Current: $1.75
Upside: n/a
Mar 24, 2025
Maintained: Hold
Price Target: $65 → $60
Current: $83.71
Upside: n/a
Mar 24, 2025
Maintained: Buy
Price Target: 100p
Current: $47.10
Upside: n/a
Apr 16, 2021
Maintained: Hold
Price Target: €150.00
Current: $145.65
Upside: n/a